Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design

被引：0
|
作者：
Montalban, X. [11 ]
Linker, R. [1 ]
Centonze, D. [2 ,3 ]
Turner, B. [4 ]
Sanchez-de la Rosa, R. [5 ]
Nillos, L. [6 ]
Ettle, B. [7 ]
Raponi, E. [8 ]
Thouvenot, E. [9 ,10 ]
机构：
[1] Univ Regensburg, Univ Str, Regensburg, Germany
[2] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy
[3] IRCCS Neuromed, Neurol Unit, Rome, Italy
[4] Royal London Hosp, Dept Neurol, London, England
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Corp Malaysia Sdn Bhd, Petaling Jaya, Selangor, Malaysia
[7] Novartis Pharma GmbH, Nurnberg, Germany
[8] Novartis Pharma SAS, Rueil Malmaison, France
[9] Univ Montpellier, CNRS, Inst Genom Fonct, INSERM, Montpellier, France
[10] Nimes Univ Hosp, Dept Neurol, Nimes, France
[11] Hosp Univ Vall Hebron, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR-224
引用
收藏
页码：357 / 358
页数：2
相关论文
共 50 条
  • [1] Long-term safety, compliance, and effectiveness of ofatumumab in patients with relapsing multiple sclerosis: alithios phase 3b study
    Fox, E. J.
    Mayer, L.
    Aungst, A.
    Mancione, L.
    Rennie, N.
    Roustan, A.
    Stoneman, D.
    Su, W.
    Das Gupta, A.
    Zalesak, M.
    Ziehn, M. O.
    Robertson, D.
    Cohen, J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 223 - 224
  • [2] Effectiveness, Safety and Patient-reported Outcomes of Ofatumumab in Relapsing Multiple Sclerosis Patients Switching from Dimethyl Fumarate or Fingolimod: ARTIOS Phase 3b Study Design
    Craner, M.
    Bove, R.
    Langdon, D.
    Detka, D.
    Ricart, J.
    Mistry, A.
    Maxwell, P.
    Pisal, C. B.
    Desireddy, P.
    Stoneman, D.
    Ziehn, M.
    Derfuss, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 35 - 35
  • [3] Efficacy, safety, and tolerability of remibrutinib (LOU064) in CSU patients: Study design of phase 3B extension trial
    Maurer, M.
    Gimenez-Arnau, A. M.
    Saini, S.
    Lebwohl, M.
    Sussman, G.
    Hide, M.
    Lheritier, K.
    Zharkov, A.
    Bhat, S.
    Wei, L.
    Martzloff, E. D.
    Haemmerle, S.
    ALLERGY, 2023, 78
  • [4] Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma
    Kutlu, Onur C.
    Chan, Jennifer A.
    Aloia, Thomas A.
    Chun, Yun S.
    Kaseb, Ahmed O.
    Passot, Guillaume
    Yamashita, Suguru
    Vauthey, Jean-Nicolas
    Conrad, Claudius
    CANCER, 2017, 123 (10) : 1817 - 1827
  • [5] Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL plus CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Breccia, Massimo
    Martino, Bruno
    Rossi, Giuseppe
    Stagno, Fabio
    Turri, Diamante
    Tiribelli, Mario
    Trabacchi, Elena
    Isidori, Alessandro
    Pierri, Ivana
    Leonardi, Giovanna
    Pregno, Patrizia
    Carella, Angelo Michele
    Bochicchio, Maria Teresa
    Testoni, Nicoletta
    Soverini, Simona
    Specchia, Giorgina
    Alimena, Giuliana
    Cavo, Michele
    Martinelli, Giovanni
    Pane, Fabrizio
    Saglio, Giuseppe
    Baccarani, Michele
    Rosti, Gianantonio
    BLOOD, 2014, 124 (21)
  • [6] Cost-Effectiveness Analysis of Entecavir versus Lamivudine in the First-Line Treatment of Australian Patients with Chronic Hepatitis B
    Arnold, Elizabeth
    Yuan, Yong
    Iloeje, Uchenna
    Cook, Greg
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2008, 6 (04) : 231 - 246
  • [7] Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B
    Elizabeth Arnold
    Yong Yuan
    Uchenna Iloeje
    Greg Cook
    Applied Health Economics and Health Policy, 2008, 6 (4) : 231 - 246
  • [8] NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
    de Castro Jr, Gilberto
    Rizvi, Naiyer A.
    Schmid, Peter
    Syrigos, Konstantinos
    Martin, Claudio
    Yamamoto, Nobuyuki
    Cheng, Ying
    Moiseyenko, Vladimir
    Summers, Yvonne
    Vynnychenko, Ihor
    Lee, Sung Yong
    Bryl, Maciej
    Zer, Alona
    Erman, Mustafa
    Timcheva, Constanta
    Raja, Rajiv
    Naicker, Kirsha
    Scheuring, Urban
    Walker, Jill
    Mann, Helen
    Chand, Vikram
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 106 - 119
  • [9] First-line treatment with ribociclib and letrozole in advanced breast cancer: First interim data from US patients enrolled in the phase 3b CompLEEment-1 clinical trial
    Lu, J.
    Shtivelband, M. I.
    Mitri, Z.
    Chap, L.
    Purkayastha, D.
    Sawhney, A. G.
    Beck, J. T.
    CANCER RESEARCH, 2019, 79 (04)
  • [10] Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Choueiri, T.
    Larkin, J.
    Albiges, L.
    Haanen, J. B.
    Schmidinger, M.
    Atkins, M. B.
    Mariani, M.
    Shnaidman, M.
    Di Pietro, A.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2016, 27
12345